SEELQ (Seelos Therapeutics) ROCE %: 0.00% (As of Jun. 2024)


SEELQ Seelos Therapeutics Inc SEELQ
16 GF Score
Price $0.00
View Full Analysis

What is Seelos Therapeutics ROCE %?

Seelos Therapeutics SEELQ 16 ROCE % is 0.00% as of Jun. 2024. GuruFocus rates SEELQ with a GF Score™ of 16/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Seelos Therapeutics's annualized ROCE % for the quarter that ended in Jun. 2024 was 0.00%.

Seelos Therapeutics  (OTCPK:SEELQ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Seelos Therapeutics ROCE % Related Terms

Seelos Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Seelos Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seelos Therapeutics ROCE % Chart

Seelos Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3,525.53 -364.77 -151.15 -201.98 0.00

Seelos Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SEELQ
16GF Score
Seelos Therapeutics Inc SEELQ
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seelos Therapeutics ROCE % Calculation

Seelos Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-37.807/( ( (22.746 - 25.158) + (5.418 - 38.928) )/ 2 )
=-37.807/( (-2.412+-33.51)/ 2 )
=-37.807/-17.961
=210.49 %

Seelos Therapeutics's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2024 )  (Q: Mar. 2024 )(Q: Jun. 2024 )
=6.932/( ( (3.612 - 36.716) + (2.381 - 30.514) )/ 2 )
=6.932/( ( -33.104 + -28.133 )/ 2 )
=6.932/-30.6185
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Seelos Therapeutics (SEELQ) has a ROCE % of 0.00% as of Jun. 2024.
Is Seelos Therapeutics' ROCE % too high?
Seelos Therapeutics' current ROCE % is 0.00%. Overall, Seelos Therapeutics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Seelos Therapeutics' ROCE % compare to NTBLQ and EFTR?
Seelos Therapeutics' ROCE % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Seelos Therapeutics's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seelos Therapeutics stock overvalued right now?
Seelos Therapeutics (SEELQ) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Seelos Therapeutics' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Seelos Therapeutics (SEELQ), the current ROCE % is 0.00% as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seelos Therapeutics Business Description

Address 300 Park Avenue, 2nd Floor, New York, NY, USA, 10022
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includes SLS-002, SLS-005, SLS-004, SLS-007, and SLS-009.
16GF Score

Get the complete analysis for SEELQ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price